Research

Contact

Dr. Eleonora SchönherrPresse & ÖffentlichkeitsarbeitPhone: +49 40 42818-264
Mail: presse(at)bnitm.de

Dr. Jessica TiedkePresse & ÖffentlichkeitsarbeitPhone: +49 40 42818-264
Mail: presse(at)bnitm.de

Analysis of Leishmania Drug Resistance and the Search for New Compounds

With an estimated 12 Mio affected humans, leishmaniases belong to the most relevant NTDs. Some Leishmania species only affect the skin, others the skin-mucosal transitions causing mutilating disfigurations. Yet others infect inner organs and cause life-threatening generalized diseases.

Massive infection of immune cells (macrophages) with leishmaniae. Cells are seen as grey areas, the cells` nuclei as large violet circles, leishmaniae as small violet spots with a grey corona.
Massive infection of immune cells (macrophages) with leishmaniae. Cells are seen as grey areas, the cells` nuclei as large violet circles, leishmaniae as small violet spots with a grey corona.

The old but still widespread treatment with antimonial drugs (arsenic-like toxins) is threatened by increasing resistance of the parasites. On the search for the underlying resistance causes and in pursuit of new drugs, we have contributed on both fronts. Thus, we have detected a small group of leishmania genes grouped around an already known drug-resistance gene. To combat resistance, we participate in a research network identifying and studying potentially effective new compounds. We found that certain plant products, so-called flavonoles, are active against Leishmania infection in vitro and may be leads for drug development.


Tejera Nevado P. et al., Antimicrob Agents Chemother 2016, 60:5262-75

Borsari C. et al., J Med Chem 2016, 59:7598-616

Paloma Tejera Nevado, Eugenia Bifeld, Katharina Höhn, Julia Eick, Joachim Clos and external cooperation partners (see publication)